FDA staff argue Avastin benefit in breast cancer not worth the risk
29 June 2011
Dan Moskowitz
Please Login to read the full article.
29 June 2011
Dan Moskowitz
Please Login to read the full article.
RELATED CONTENT
NEWS
- California Blue Shield to no longer pay for Avastin in breast cancer
- Iron chelator, prostate cancer conundrum on deck for ODAC
- US FDA lawyers urge no 'do-over' for Avastin breast cancer indication
- Poor efficacy undermines Genentech metastatic breast cancer indication for Avastin
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
